ALO 212

Drug Profile

ALO 212

Alternative Names: ALO212

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Arteriocyte
  • Developer Compass Biomedical
  • Class Anti-ischaemics; Stem cell therapies
  • Mechanism of Action Angiogenesis inducing agents; Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Peripheral vascular disorders

Most Recent Events

  • 12 Dec 2016 Arteriocyte is now called Compass Biomedical
  • 02 Apr 2013 Phase-I development is ongoing in USA
  • 21 Jan 2011 Phase-I clinical trials in Peripheral vascular disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top